The risk of over-production has paid off: world orders for swine vaccines will see billions of dollars in extra revenue for the biggest pharma companies. GlaxoSmithKline, Roche, Sanofi-Aventis, Novartis, and Baxter are all expected to report very healthy first-half earnings as a result of a wealth of government contracts for vaccines and antiviral medicines.

According to a report in the UK Financial Times, GSK has sold 150m doses of its pandemic flu to the UK, US, France and Belgium, and sales of Roche’s Tamiflu have been boosted by orders from the both the public and private sectors. From the US government alone,
Novartis has received an order for $346 million for antigen and $343.8 million for adjuvant, a total sale of nearly $690 million. Total swine flu vaccine sales could ultimately net Novartis between $1 and $1.5 billion.

But, ahead of the publication of the company financial reports, there already seems to be indications of potential backlash about pharma’s return on investment with regard to the swine flu orders. In the UK media, GSK has already been obliged to justify the price of approx. £6 per dose that it has set for its vaccine, with CEO Andrew Witty explaining: “We’ve deliberately been very responsible about pricing — the vaccine is not being sold at a special premium…”

The pandemic has been saturating the UK news much more than in other countries; in the US, it has featured nowhere near as prominently on the agenda. The UK media is notorious for turning against those that it previously championed. One wonders, then, whether this price-based backlash is likely to spiral over the coming months, as the vaccines finally hit the market.

It’s very possible, in the UK at least, that the knights in shining pharma that promised to come to the swine flu rescue just a few weeks ago could be soon be subject to the wrong kind of press attention — once again!

Roche wants Genentech and it’s sick of waiting for a deal.

Six months after a special committee for the biotech firm’s board of directors rejected Roche’s offer of $43.7 billion or $89 a share, Roche has switched gears and dropped the offer to $86.50 per share and is taking negotiations to the stockholders.

“We are disappointed that the discussions over the last six months between Roche and the special committee of Genentech have not produced a negotiated agreement,” Roche Chairman Franz B. Humer stated in a release. “We feel it is now time to give the Genentech minority shareholders the opportunity to decide on our offer. Especially in the current market environment the offer provides an opportunity for all public shareholders to achieve liquidity and to receive a fair price for all their shares.”

Roche already owns 55 percent of Genentech and hopes to snag full control of its top cancer treatment Avastin. When the deal is approved, Roche plans to leave Genentech’s R&D division as a stand alone unit based in San Francisco. Meanwhile, Roche’s Nutley, New Jersey-based pharma commercial operations and Palto Alto-based virology division would be transplanted to SF. The Nutley branch will not be shuttered, instead it’s going to be turned into ground zero for Roche’s disease biology and metabolism units.

Roche plans to pay for the aquisition merger using a combination of cash, loans, and bonds.